Researchers from the Organoid Group and the Rare Cancers Genomics Team have created a new model for studying neuroendocrine tumors (NETs) in the lab. The researchers found that some types of NETs need the protein Epidermal Growth Factor (EGF) to grow, potentially making them treatable with inhibitors of the EGF receptor. This discovery is surprising since tumors are usually thought to be independent of growth factors. The new model provides a way to study the disease and could lead to new treatment options for patients with pulmonary NETs. Further research is needed to confirm these findings and develop effective therapies.
Source link
Organoids study finds potential new treatment for pulmonary neuroendocrine tumors
